Tocagen, which is developing gene therapies for the treatment of brain cancer, announced terms for its IPO on Monday.
The San Diego, CA-based company plans to raise $80 million by offering 7.3 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Tocagen would command a fully diluted market value of $189 million and an enterprise value of $95 million.
Tocagen was founded in 2007 and it plans to list on the Nasdaq under the symbol TOCA. Leerink Partners, Evercore ISI and Stifel are the joint bookrunners on the deal. It is expected to price during the week of April 10, 2017.
